Previous preclinical studies have indicated that an administrated intratumoral influenza vaccine can increase antitumor CD8+, decrease the level of regulatory B cells within the tumor, increase T cell microenvironment infiltration, increase local IFN-ƴ, and reduce the tumor mass [14,15]. This evidence concerns the gene IFNA1 and neoplasm.